TY - JOUR
KW - Analgesics, Opioid/administration & dosage/adverse effects
KW - Animals
KW - Buprenorphine/administration & dosage
KW - Delayed-Action Preparations
KW - Drug Delivery Systems
KW - Humans
KW - Opiate Substitution Treatment/methods
KW - Opioid-Related Disorders/drug therapy/economics
KW - buprenorphine
KW - depot medications
KW - drug diversion
KW - Drug Implants
KW - Maintenance Therapy
KW - opioid use disorder
KW - treatment adherence
AU - Richard N. Rosenthal
AU - Viral V. Goradia
A1 - 
AB - Opioid use disorders (OUDs) have long been a global problem, but the prevalence rates have increased over 20 years to epidemic proportions in the US, with concomitant increases in morbidity and all-cause mortality, but especially opioid overdose. These increases are in part attributable to a several-fold expansion in the prescription of opioid pain medications over the same time period. Opioid detoxification and psychosocial treatments alone have each not yielded sufficient efficacy for OUD, but mu-opioid receptor agonist, partial agonist, and antagonist medications have demonstrated the greatest overall benefit in OUD treatment. Buprenorphine, a mu-opioid receptor partial agonist, has been used successfully on an international basis for several decades in sublingual tablet and film preparations for the treatment of OUD, but the nature of formulation, which is typically self-administered, renders it susceptible to nonadherence, diversion, and accidental exposure. This article reviews the clinical trial data for novel buprenorphine delivery systems in the form of subcutaneous depot injections, transdermal patches, and subdermal implants for the treatment of OUD and discusses both the clinical efficacy of longer-acting formulations through increasing consistent medication exposure and their potential utility in reducing diversion. These new delivery systems also offer new dosing opportunities for buprenorphine and strategies for dosing intervals in the treatment of OUD.
AD - Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York.; Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA.
BT - Drug design, development and therapy
C5 - Opioids & Substance Use
CY - New Zealand
DO - 10.2147/DDDT.S72543
JF - Drug design, development and therapy
LA - eng
M1 - Journal Article
N2 - Opioid use disorders (OUDs) have long been a global problem, but the prevalence rates have increased over 20 years to epidemic proportions in the US, with concomitant increases in morbidity and all-cause mortality, but especially opioid overdose. These increases are in part attributable to a several-fold expansion in the prescription of opioid pain medications over the same time period. Opioid detoxification and psychosocial treatments alone have each not yielded sufficient efficacy for OUD, but mu-opioid receptor agonist, partial agonist, and antagonist medications have demonstrated the greatest overall benefit in OUD treatment. Buprenorphine, a mu-opioid receptor partial agonist, has been used successfully on an international basis for several decades in sublingual tablet and film preparations for the treatment of OUD, but the nature of formulation, which is typically self-administered, renders it susceptible to nonadherence, diversion, and accidental exposure. This article reviews the clinical trial data for novel buprenorphine delivery systems in the form of subcutaneous depot injections, transdermal patches, and subdermal implants for the treatment of OUD and discusses both the clinical efficacy of longer-acting formulations through increasing consistent medication exposure and their potential utility in reducing diversion. These new delivery systems also offer new dosing opportunities for buprenorphine and strategies for dosing intervals in the treatment of OUD.
PP - New Zealand
PY - 2017
SN - 1177-8881; 1177-8881
SP - 2493
EP - 2505
EP - 
T1 - Advances in the delivery of buprenorphine for opioid dependence
T2 - Drug design, development and therapy
TI - Advances in the delivery of buprenorphine for opioid dependence
U1 - Opioids & Substance Use
U2 - 28894357
U3 - 10.2147/DDDT.S72543
VL - 11
VO - 1177-8881; 1177-8881
Y1 - 2017
Y2 - Aug 28
ER -